ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) OCF Margin %: -61.47% (As of Dec. 2025)


HKSE:01541 ImmuneOnco Biopharmaceuticals (Shanghai) Inc HKSE:01541
7 GF Score
Price HK$3.56
! 5 Warning Signs
View Full Analysis

What is ImmuneOnco Biopharmaceuticals (Shanghai) OCF Margin %?

ImmuneOnco Biopharmaceuticals (Shanghai) HKSE:01541 -3.26% 7 OCF Margin % is -61.47% as of Dec. 2025. GuruFocus rates HKSE:01541 with a GF Score™ of 7/100. The stock has 5 warning signs investors should review. Among 960 Biotechnology companies, ImmuneOnco Biopharmaceuticals (Shanghai) ranks worse than 57.4% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. ImmuneOnco Biopharmaceuticals (Shanghai)'s Cash Flow from Operations for the six months ended in Dec. 2025 was HK$-79.0 Mil. ImmuneOnco Biopharmaceuticals (Shanghai)'s Revenue for the six months ended in Dec. 2025 was HK$128.4 Mil. Therefore, ImmuneOnco Biopharmaceuticals (Shanghai)'s OCF Margin % for the quarter that ended in Dec. 2025 was -61.47%.

As of today, ImmuneOnco Biopharmaceuticals (Shanghai)'s current OCF Yield % is -14.49%.

The historical rank and industry rank for ImmuneOnco Biopharmaceuticals (Shanghai)'s OCF Margin % or its related term are showing as below:

HKSE:01541' s OCF Margin % Range Over the Past 10 Years
Min: -95266.11   Med: -3760.65   Max: -131.3
Current: -130.74

During the past 5 years, the highest OCF Margin % of ImmuneOnco Biopharmaceuticals (Shanghai) was -131.30%. The lowest was -95266.11%. And the median was -3760.65%.

HKSE:01541's OCF Margin % is ranked worse than
57.4% of 960 companies
in the Biotechnology industry
Industry Median: -68.59 vs HKSE:01541: -130.74

ImmuneOnco Biopharmaceuticals (Shanghai) OCF Margin % Related Terms

ImmuneOnco Biopharmaceuticals (Shanghai) OCF Margin % Historical Data

* Premium members only.

The historical data trend for ImmuneOnco Biopharmaceuticals (Shanghai)'s OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ImmuneOnco Biopharmaceuticals (Shanghai) OCF Margin % Chart

ImmuneOnco Biopharmaceuticals (Shanghai) Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
-3,760.65 -44,354.58 -95,266.11 -172.67 -131.30

ImmuneOnco Biopharmaceuticals (Shanghai) Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
OCF Margin % Get a 7-Day Free Trial Premium Member Only -78,431.40 -159,557.83 -6.77 -344.80 -61.47

HKSE:01541 vs VRTX, REGN, ALNY: OCF Margin % Comparison

For the Biotechnology subindustry, ImmuneOnco Biopharmaceuticals (Shanghai)'s OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ImmuneOnco Biopharmaceuticals (Shanghai) OCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmuneOnco Biopharmaceuticals (Shanghai)'s OCF Margin % distribution charts can be found below:

* The bar in red indicates where ImmuneOnco Biopharmaceuticals (Shanghai)'s OCF Margin % falls into.


HKSE:01541
7GF Score
ImmuneOnco Biopharmaceuticals (Shanghai) Inc HKSE:01541
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ImmuneOnco Biopharmaceuticals (Shanghai) OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

ImmuneOnco Biopharmaceuticals (Shanghai)'s OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-223.799/170.452
=-131.30 %

ImmuneOnco Biopharmaceuticals (Shanghai)'s OCF Margin for the quarter that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-78.95/128.443
=-61.47 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of -61.47% mean?
ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) has a OCF Margin % of -61.47% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on ImmuneOnco Biopharmaceuticals (Shanghai) and its competitors. According to the industry distribution chart, ImmuneOnco Biopharmaceuticals (Shanghai) ranks #551 out of 960 companies in the Biotechnology industry, placing it in the top 57.4%.
Is ImmuneOnco Biopharmaceuticals (Shanghai)'s OCF Margin % too high?
ImmuneOnco Biopharmaceuticals (Shanghai)'s current OCF Margin % is -61.47%. Based on the distribution chart, ImmuneOnco Biopharmaceuticals (Shanghai) ranks #551 out of 960 companies in the Biotechnology industry, which is below the industry midpoint. Overall, ImmuneOnco Biopharmaceuticals (Shanghai) has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does ImmuneOnco Biopharmaceuticals (Shanghai)'s OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ImmuneOnco Biopharmaceuticals (Shanghai) ranks #551 out of 960 companies for OCF Margin %. This places ImmuneOnco Biopharmaceuticals (Shanghai) in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on ImmuneOnco Biopharmaceuticals (Shanghai) and its competitors. ImmuneOnco Biopharmaceuticals (Shanghai)'s current OCF Margin % is -61.47%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ImmuneOnco Biopharmaceuticals (Shanghai) stock overvalued right now?
ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) has a current OCF Margin % of -61.47%. The current OCF Margin % is -61.47%. ImmuneOnco Biopharmaceuticals (Shanghai)'s overall GF Score™ is 7/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541), the current OCF Margin % is -61.47% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ImmuneOnco Biopharmaceuticals (Shanghai) Business Description

Address 1000 Zhangheng Road, Unit 15, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai, CHN
ImmuneOnco Biopharmaceuticals (Shanghai) Inc is a science-driven biotechnology company dedicated to the development of immuno-oncology therapies. It is one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems. It has designed a robust pipeline of over ten drug candidates with 12 ongoing clinical programs., featured by a comprehensive innate-immunity-based asset portfolio. Its pipeline reflects its extensive understanding of the frontiers of cancer biology and immunology and its expertise in turning scientific research into drug candidates.
7GF Score

Get the complete analysis for HKSE:01541

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$3.56
Price